Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

291.16 -5.81 (-1.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily... 
Via Benzinga
This US Representative Just Bought Shares Of Airbnb And These 2 Dividend-Paying Stocks
Congressman Josh Gottheimer (D-NJ) has made over 1,200 trades in the past three years, with his top two traded stocks being Microsoft (NASDAQ: MSFT) and Apple (NASDAQ: AAPL), reported b 
Via Benzinga
2 Ultra-Safe Passive Income Stocks to Buy Right Now
These two top biopharma stocks are crushing the 2022 bear market. 
Via The Motley Fool
Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts
The company offered a stronger-than-expected guidance boost for the year. 
Via Investor's Business Daily
Analyst Ratings for Amgen
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
Bitcoin hit a two-year low while Meta and Tesla were in focus. 
Via Investor's Business Daily
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Market Briefing For Wednesday, Nov. 9
For the moment, S&P should attempt yet-another trust, react to the CPI just a day later and then possibly go on the defensive, but not for a catastrophe. 
Via Talk Markets
Dow Logs Highest Close Since Late August
The Dow stayed hot today, nabbing its third-straight win on the back of a 333-point gain. 
Via Talk Markets
What 6 Analyst Ratings Have To Say About Amgen
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Will Chart Analysts Notice Bad Omen on Amgen's Chart
If history is any guide, there may be trouble ahead for shares of Amgen (NASDAQ:AMGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Is Amgen Stock a Buy Now?
A recent analyst upgrade has boosted the stock. 
Via The Motley Fool
How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug
Early-stage results look promising for Amgen's experimental obesity treatment. 
Via Investor's Business Daily
Amgen's Olpasiran Reduced Cholesterol Levels In 95% Of Patients In Mid-Stage Study
Amgen Inc (NASDAQ: AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic... 
Via Benzinga
Musk Reportedly Suspends Twitter Work On Crypto Wallet, Boeing's Jeppesen Hit By Potential Ransomware Attack, Lyft Cuts Workforce: Top Stories Friday, Nov. 04
Reuters 
Via Benzinga
Amgen Reports Q3 Higher Profit, Despite Slight Fall In Topline Growth
Via Benzinga
2 Dividend Stocks to Hold Through a Recession and Beyond
If a recession does come, it won't be the first that these two companies will have survived one. 
Via The Motley Fool
Looking At Amgen's Recent Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. 
Via TheNewswire.com
Exposures Product Safety
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
By Mark Gilman, Benzinga 
Via News Direct
Exposures Product Safety
Dogs Of The Dow: A Leading Strategy In 2022
At that time the Dow Dogs strategy had a positive year-to-date return versus the negative return of the Dow Jones Industrial Average Index and the S&P 500 Index. 
Via Talk Markets
Could Amgen Continue To Soar In This Bear Market?
Amgen did a mini pull back then broke out on 24 Oct and committed above $260. According to the Wyckoff trading method, there is no immediate threatening supply hence the price could continue to climb... 
Via Talk Markets
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.   
Via Benzinga
Dissecting The Dow Jones Industrial Average: Half Empty Or Half Full?
The Dow Jones Industrial Average is a leading index comprised of 30 stocks. Consequently, it has long been considered a great proxy for the stock market at large. 
Via Talk Markets
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.09% on an annualized basis producing an average annual return of 8.55%. Currently, Amgen has a market capitalization of... 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.